STRM.BIO Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series 2
- Latest Deal Amount
-
$8M
- Investors
-
16
STRM.BIO General Information
Description
Developer of a non-viral in vivo gene delivery platform designed to enable targeted transport of genetic material to bone marrow cells for therapeutic research and development. The company's platform is built on cell-derived extracellular vesicle technology capable of carrying deoxyribonucleic acid, ribonucleic acid, and protein cargos, supporting repeat dosing, scalable manufacturing, tunable tissue targeting, and preferential biodistribution to bone marrow while avoiding off-target organs, enabling biopharmaceutical researchers and clinical development groups focused on hematologic and immune-related diseases to advance precise in vivo cell and gene therapy programs with improved delivery control and biological compatibility
Contact Information
Website
www.strm.bioCorporate Office
- 750 Main Street
- The Engine
- Boston, MA 02139
- United States
Corporate Office
- 750 Main Street
- The Engine
- Boston, MA 02139
- United States
STRM.BIO Timeline
STRM.BIO Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Seed Round | 07-Jan-2026 | $8M | Completed | Pre-Clinical Trials | ||
| 7. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 6. Seed Round | 02-Feb-2023 | Completed | Pre-Clinical Trials | |||
| 5. Accelerator/Incubator | 01-Sep-2022 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 01-Jul-2022 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 31-Mar-2021 | Completed | Pre-Clinical Trials | |||
| 2. Grant | 01-Jul-2020 | $265K | Completed | Pre-Clinical Trials | ||
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
STRM.BIO Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
STRM.BIO Comparisons
Industry
Financing
Details
STRM.BIO Competitors (1)
One of STRM.BIO’s competitors is Capstan (Logistics), a Formerly VC-backed company based in Gardena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Capstan (Logistics) | Formerly VC-backed | Gardena, CA |
STRM.BIO Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
STRM.BIO Patents
STRM.BIO Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260347882-A1 | Compositions and methods related to megakaryocyte-derived extracellular vesicles for treating myeloproliferative neoplasms | Pending | 01-May-2026 | ||
| AU-2022386233-A1 | Biomarkers of megakaryocyte-derived extracellular vesicles | Pending | 11-Nov-2021 | ||
| CA-3237748-A1 | Biomarkers of megakaryocyte-derived extracellular vesicles | Pending | 11-Nov-2021 | ||
| EP-4429641-A1 | Biomarkers of megakaryocyte-derived extracellular vesicles | Pending | 11-Nov-2021 | ||
| EP-4429641-A4 | Biomarkers of megakaryocyte-derived extracellular vesicles | Pending | 11-Nov-2021 | A61K31/7115 |
STRM.BIO Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
STRM.BIO Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Blue Bay Ventures | Venture Capital | Minority | ||
| Recordati | Corporation | Minority | ||
| Alix Ventures | Venture Capital | Minority | ||
| NYBC Ventures | Corporate Venture Capital | Minority | ||
| The Engine | Accelerator/Incubator |
STRM.BIO FAQs
-
When was STRM.BIO founded?
STRM.BIO was founded in 2019.
-
Where is STRM.BIO headquartered?
STRM.BIO is headquartered in Boston, MA.
-
What is the size of STRM.BIO?
STRM.BIO has 9 total employees.
-
What industry is STRM.BIO in?
STRM.BIO’s primary industry is Drug Discovery.
-
Is STRM.BIO a private or public company?
STRM.BIO is a Private company.
-
What is the current valuation of STRM.BIO?
The current valuation of STRM.BIO is .
-
What is STRM.BIO’s current revenue?
The current revenue for STRM.BIO is .
-
How much funding has STRM.BIO raised over time?
STRM.BIO has raised $25.2M.
-
Who are STRM.BIO’s investors?
Blue Bay Ventures, Recordati, Alix Ventures, NYBC Ventures, and The Engine are 5 of 16 investors who have invested in STRM.BIO.
-
Who are STRM.BIO’s competitors?
Capstan (Logistics) is a competitor of STRM.BIO.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
